Obesity and heart failure with preserved ejection fraction (HFpEF) represent two
intermingling epidemics driving perhaps the greatest unmet health problem in …

Pulmonary vascular remodeling is the critical structural alteration and pathological feature in
pulmonary hypertension (PH) and involves changes in the intima, media and adventitia …

Patients with heart failure with preserved ejection fraction (HFpEF) universally complain of
exercise intolerance and dyspnoea as key clinical correlates. Cardiac as well as …

Previous studies highlight the potential for sodium-glucose cotransporter type 2 (SGLT2)
inhibitors (SGLT2i) to exert cardioprotective effects in heart failure by increasing plasma …

Pulmonary hypertension (PH) is a progressive lethal disease, which is characterized by
abnormal vascular remodeling and persistently elevated pulmonary artery pressure …

Heart failure (HF) with preserved ejection fraction (HFpEF) is currently a preeminent
challenge for cardiovascular medicine. It has a poor prognosis, increasing mortality, and is …

Heart failure is a major global health concern. Noncoding RNAs (ncRNAs) are involved in
physiological processes and in the pathogenesis of various diseases, including heart failure …

The burden of growing concern about the dysregulation of metabolic processes arises due
to complex interplay between environment and nutrition that has great impact on genetics …

Subarachnoid haemorrhage (SAH) is a common and devastating complication of
haemorrhagic stroke. SAH is characterised by high mortality rates, permanent disabilities …

This science advisory focuses on the need to better understand the epidemiology,
pathophysiology, and treatment of pulmonary hypertension in patients with heart failure with …